February 23, 2015

Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Key Points

Key points are not available for this paper at this time.

Abstract

The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

John R. White (Mon,) studied this question.

synapsesocial.com/papers/69d570d875589c71d767df6c — DOI: https://doi.org/10.1177/1060028015573564

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial· 2014 · 86 citations
Uric Acid and Cardiovascular Risk· 2008 · 2,439 citations
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].· 2012 · 580 citations
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production· 2014 · 777 citations
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial· 2014 · 375 citations

Authors

John R. White

Franciscan University of Steubenville

Journals

Annals of Pharmacotherapy

Actions

Institutions

Washington State University Spokane

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider